Key Takeaways
- • Akin Gump advised Pharmakon Advisors and BioPharma Credit funds on a unitranche debt facility financing ARCHIMED's acquisition of Esperion Therapeutics, valued at up to $1.1 billion in total equity value on a fully diluted basis, contingent on achievement of commercial-based milestones.
- • The transaction structure combines debt and equity financing for ARCHIMED's acquisition of Esperion, a commercial-stage biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies, demonstrating continued institutional appetite for healthcare credit in the life sciences sector.
- • Pharmakon Advisors, a specialized non-dilutive debt investor in life sciences, led the debt financing component alongside BioPharma Credit funds, reflecting the growing role of dedicated healthcare credit vehicles in funding pharma acquisitions.
- • The deal milestone structure ties equity valuation to commercial performance achievement, aligning investor returns with Esperion's ability to execute on commercial objectives post-acquisition.
Summary
Akin Gump Strauss Hauer & Feld advised Pharmakon Advisors and the BioPharma Credit funds in connection with a unitranche debt facility supporting ARCHIMED's acquisition of Esperion Therapeutics. The transaction is valued at up to approximately $1.1 billion in total equity value on a fully diluted basis, with the final valuation contingent on Esperion's achievement of specified commercial-based milestones. This structure reflects a market trend toward performance-linked valuations in healthcare M&A, particularly where acquirers seek to de-risk pharmaceutical acquisitions through earnout mechanisms tied to commercial execution.
Esperion Therapeutics is a commercial-stage biopharmaceutical company specializing in cardiometabolic and rare or orphan disease therapies. ARCHIMED, which exclusively focuses on healthcare investments, acquired the company as part of its strategic expansion in the therapeutic areas Esperion operates. The debt financing was structured as a unitranche facility, a common approach in healthcare M&A that provides borrowers with a single-tranche debt instrument combining characteristics of traditional term loans and subordinated debt, simplifying financing complexity and reducing execution risk.
Pharmakon Advisors specializes in non-dilutive debt financing for life sciences companies, positioning it as a natural institutional partner for healthcare acquisitions requiring creative capital structures. The involvement of both Pharmakon Advisors and the BioPharma Credit funds underscores the institutional appetite for specialized healthcare credit instruments, particularly in transactions where traditional bank financing may be constrained by regulatory considerations or sector-specific credit metrics.
The Akin team was led by tax partner Geoffrey Secol and comprised specialists across tax, healthcare and life sciences, finance, international trade, and corporate functions, reflecting the multidisciplinary legal complexity inherent in cross-border healthcare acquisitions involving performance-based equity tranches and specialized debt structures.
Esperion Therapeutics is a commercial-stage biopharmaceutical company specializing in cardiometabolic and rare or orphan disease therapies. ARCHIMED, which exclusively focuses on healthcare investments, acquired the company as part of its strategic expansion in the therapeutic areas Esperion operates. The debt financing was structured as a unitranche facility, a common approach in healthcare M&A that provides borrowers with a single-tranche debt instrument combining characteristics of traditional term loans and subordinated debt, simplifying financing complexity and reducing execution risk.
Pharmakon Advisors specializes in non-dilutive debt financing for life sciences companies, positioning it as a natural institutional partner for healthcare acquisitions requiring creative capital structures. The involvement of both Pharmakon Advisors and the BioPharma Credit funds underscores the institutional appetite for specialized healthcare credit instruments, particularly in transactions where traditional bank financing may be constrained by regulatory considerations or sector-specific credit metrics.
The Akin team was led by tax partner Geoffrey Secol and comprised specialists across tax, healthcare and life sciences, finance, international trade, and corporate functions, reflecting the multidisciplinary legal complexity inherent in cross-border healthcare acquisitions involving performance-based equity tranches and specialized debt structures.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.